Clinical trials: Alcohol Dependency
Alcoholism
Alcohol Interaction Study
The purpose of this study is understand the effects of GSK114814 and alcohol in healthy volunteers when taken together.
- Trial name
- NCT01181908
- Testing
- single dose
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcohol Use Disorder
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.
- Trial name
- NCT02511886
- Testing
- Arbaclofen Placarbil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indivior Inc.
Alcohol Dependence
A Study in the Treatment of Alcohol Dependence.
H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management.
- Trial name
- NCT00805441
- Testing
- LY686017
- Where
- 21 sites in United States
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Alcohol Dependence
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)
This was a Phase 3 multicenter extension of Alkermes' Study ALK21-003 (NCT01218958 [the base study]) that evaluated the safety of Medisorb® naltrexone (VIVITROL®) administered every 4 weeks for 48 weeks (13 injections) in…
- Trial name
- NCT01218971
- Testing
- Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg
- Volunteers
- 332 people
- Sponsor
- Alkermes, Inc.
Alcohol Dependence
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence
The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.
- Trial name
- SENSE (NCT00811941)
- Testing
- Nalmefene
- Where
- 60 sites in Czechia, Estonia and 8 more
- Volunteers
- 665 people
- Sponsor
- H. Lundbeck A/S
Alcohol Use Disorder
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
- Trial name
- RENEW-ALC-1 (NCT07219966)
- Testing
- LY3537031
- Where
- 117 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Alcohol Use Disorder (AUD)
Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. The study plans to enroll 240 adult patients with Alcohol Use Disorder (AUD).
- Trial name
- AUD (NCT07433413)
- Testing
- Naltrexone
- Volunteers
- 240 people
- Sponsor
- Shenzhen Sciencare Medical Industries Co., Ltd.
Addictive Behavior, Alcohol Use Disorder
90-Day Online Substance Use Program
Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual.
- Conditions
- Addictive Behavior, Alcohol Use Disorder, Alcohol Abuse, Drug Abuse
- Trial name
- NCT03069118
- Testing
- Treatment - Workit Health Online Program, Control - Resource List
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Workit Health
Alcoholism
GSK1521498 Alcohol Interaction Study
The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together.
- Trial name
- NCT01366573
- Testing
- GSK1521498
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcohol Addiction
Soberlink - MAP Outcomes Study Protocol
The purpose of this study is to show the effectiveness of Soberlink's remote alcohol monitoring system integrated with MAP's patient engagement platform (EHR) to monitor a sample size of at-risk alcohol use disorder (AUD)…
- Trial name
- NCT03190356
- Testing
- Soberlink Cellular Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Soberlink Healthcare LLC
Alcohol Use Disorder
A Study of New Treatment for Excessive Alcohol Users by Electric Stimulation of Nerves Around Ear
Alcohol Use Disorders (AUD's) are a major health and social problem. Relapse is a rule rather than an exception in alcohol dependence, leading to poor outcomes. Craving are frequently associated with relapse.
- Trial name
- NCT04106739
- Testing
- Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
- Where
- India
- Volunteers
- 44 people
- Sponsor
- DyAnsys, Inc.
Alcoholism, Alcohol Abuse
EMPOWER AUD Pivotal Trial
Multi-site, double-blinded, prospective, randomized, sham-controlled study
- Conditions
- Alcoholism, Alcohol Abuse, Alcohol Use Disorder
- Trial name
- NCT05948605
- Testing
- Empower Neuromodulation System
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Theranova, L.L.C.
Alcohol Dependence
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group…
- Trial name
- NCT02364947
- Testing
- Nalmefene hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 678 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Alcohol Dependence
A Study of MK0594 in Patients With Alcohol Dependence (0594-020)
A study in patients with alcohol dependence to see if MK0594 is safe and effective in maintaining absence of heavy drinking over a 12-week treatment period.
- Trial name
- NCT00835718
- Testing
- Comparator: MK0594 5 mg/day, Comparator: MK0594 1 mg/day, Comparator: MK0594 1 mg/week
- Volunteers
- 162 people
- Sponsor
- Vyne Therapeutics Inc.
Alcohol Dependence
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.
- Trial name
- NCT02197598
- Testing
- nalmefene
- Where
- 3 sites in Germany
- Volunteers
- 45 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
This study will evaluate the safety and efficacy of ALKS33 (RDC-0313) compared with placebo in adults with alcohol dependence. There will be 11 study visits conducted over a period of about 4 months.
- Trial name
- NCT00981617
- Testing
- ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg)
- Where
- 27 sites in United States
- Volunteers
- 406 people
- Sponsor
- Alkermes, Inc.
Anxiety Disorders, Alcohol Use Disorder
Treating Stress and Anxiety in Individuals With Alcohol Use Disorder (AUD)
CT fibers are found in the skin of most mammals and project to the insular cortex. Stimulation of CT fibers by light touch causes a release of oxytocin and is associated with feelings of comfort and wellbeing.
- Conditions
- Anxiety Disorders, Alcohol Use Disorder, Stress, Psychological
- Trial name
- NCT06224127
- Testing
- active heat, Active c tactile fiber stimulation
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Soovu Labs Inc.
Alcohol Dependence
ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
This was a study of the effects of VIVITROL® on alcohol cue-induced craving and the associated brain activation patterns in alcohol-dependent adults who had recently completed alcohol detoxification and were seeking further…
- Trial name
- NCT00511836
- Testing
- VIVITROL 380 mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Alkermes, Inc.
Hepatic Cirrhosis, Alcoholism
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
The purpose of this study is to evaluate the effect of varying degrees of hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of pasireotide s.c. in subjects.
- Trial name
- NCT00698464
- Testing
- Pasireotide
- Where
- 4 sites in United States, Belgium and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alcohol Use Disorder
Pilot Evaluation of the Empower Neuromodulation System in AUD Patients
This study evaluates the effects of peripheral nerve stimulation on alcohol craving and consumption in participants with alcohol use disorder (AUD).
- Trial name
- NCT03983317
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.